查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1445527

术后疼痛市场评估：按产品、给药途径、分销管道和地区划分的机会和预测（2017-2031）

Postoperative Pain Market Assessment, By Product, By Route of Administration, By Distribution Channel, By Region, Opportunities and Forecast, 2017-2031F
出版日期: | 出版商: Market Xcel - Markets and Data | 英文 235 Pages | 商品交期: 3-5个工作天内

价格

全球术后疼痛市场规模将从2023年的400.9亿美元成长到2031年的603.6亿美元，2024-2031年预测期内复合年增长率为5.25%，预计规模将持续成长。

由于外科手术的增加导致对有效疼痛缓解策略的高需求以及需要有效术后疼痛控制的慢性疾病的增加等因素，预计该市场将增长。 此外，对阿片类药物滥用的担忧导致人们越来越有兴趣探索非阿片类药物用于术后疼痛管理的选择。 透过减轻术后疼痛来提高患者依从性也是推动市场的一个主要因素。 推动产业创新的研发措施也提供了减少术后不适的新方法，有助于市场的进一步成长。 另一方面，市场成长的主要障碍是与使用鸦片类止痛药相关的副作用以及与使用疼痛管理解决方案相关的其他併发症。 由于疼痛管理使用作用于神经系统的药物，因此药物滥用也是一个主要问题和监管挑战。

2023年10月，Hyloris Pharma宣布其术后疼痛治疗药物Maxigesic IV获得美国FDA核准。 Maxigesic IV 是一种静脉注射药物，结合了扑热息痛和布洛芬溶液，可减轻术后疼痛和炎症，且没有阿片类药物成瘾的风险。 Hyloris Pharma 是一家总部位于比利时的公司，与纽西兰药品製造商 AFT Pharmaceuticals 和 Hikma Pharmaceuticals 合作开发了该核准药物。

当单独的药物治疗不够时，需要进行许多手术。 全球需要手术治疗的癌症病例（例如咽癌和口腔癌）数量正在增加。 心血管和胃肠道疾病等慢性疾病的增加以及需要手术的交通事故的数量也推动了对一次性手术器械的需求。 大量手术与大量术后疼痛病例直接相关，预计术后疼痛市场将因两者的增加而扩大。 根据世界卫生组织 (WHO) 统计，全世界每年进行超过 3 亿例外科手术。 根据现有数据，2022年美国进行了超过700万个例外科手术。

随着对病人依从性的日益重视，术后疼痛管理已成为一个主要问题。 许多患者术后出现中度至重度疼痛，显示术后疼痛控制不足。 造成这问题的主要原因是止痛药处方不足，不遵守规定并不是唯一原因。 疼痛评估、记录和管理是护理的重要方面，因为出院后患者的疼痛管理可能会被忽略。 遵守术后患者疼痛评估至关重要，建议使用标准量表。 充足的镇痛药物和批准的国家疼痛指南对于有效的疼痛管理至关重要。 参与公司不断致力于产品开发和监管回应，以更好地回应市场需求。

从产品类型来看，製药业预计将占据主导地位，因为它比设备使用更广泛。 阿片类药物、非类固醇类抗发炎药 (NSAID) 等镇痛药比疼痛管理设备更容易获得且更具成本效益。 该药物不需要医疗帮助，易于给药，这也有助于其高利用率。 另一方面，为了避免与药物相关的副作用而采用疼痛管理设备的情况也在增加，从而提高了疼痛管理设备行业的成长率。 由于疼痛管理设备的日益普及、易于获取、患者依从性和成本效益，预计製药业将占据主导地位。

本报告调查了全球术后疼痛市场，提供了市场定义和概述、市场规模趋势和预测、各个细分市场和地区的详细分析、行业结构以及影响市场成长的因素。我们编制分析、案例研究、竞争格局、主要公司概况等。

目录

第 1 章研究方法

第 2 章专案范围与定义

第 3 章执行摘要

第 4 章全球术后疼痛市场展望

  • 市场规模/预测
  • 按产品
    • 药品
    • 设备
  • 依给药途径
    • 注射
    • 口头
    • 本地
    • 透皮
    • 其他
  • 按分销管道
    • 医院药房
    • 零售药局
    • 网路药局
  • 按地区
    • 北美
    • 欧洲
    • 亚太地区
    • 南美洲
    • 中东/非洲
  • 按公司划分：市场占有率 (%)，2023 年

第 5 章全球术后疼痛市场展望：按地区

  • 北美
  • 欧洲
  • 亚太地区
  • 南美洲
  • 中东/非洲

第 6 章市场映射

  • 按产品
  • 依给药途径
  • 按分销管道
  • 按地区

第 7 章宏观环境与产业结构

  • 需求与供给分析
  • 汇入/汇出分析
  • 价值链分析
  • PESTEL 分析
  • 波特五力分析

第 8 章市场动态

  • 生长促进因素
  • 生长促进因素（问题、限制因素）

第 9 章监理架构与创新

  • 临床试验
  • 专利情况
  • 监理机关的核准
  • 创新/新兴技术

第 10 章主要公司状况

  • 前 5 名市场领导者的竞争矩阵
  • 前 5 位市场领导者的市场收入分析
  • 併购/合资企业（如果适用）
  • SWOT 分析（5 家参与公司）

第 11 章价格分析

第 12 章案例研究

第 13 章主要公司展望

  • Novartis AG
  • Allergan plc
  • Teva Pharmaceutical Industries Ltd.
  • Mylan N.V.
  • Pfizer Inc.
  • GlaxoSmithKline Plc.
  • Johnson & Johnson Pte. Ltd.
  • AstraZeneca PLC
  • Sanofi S.A.
  • Cipla Inc. (InvaGen Pharmaceuticals Inc.)

第 14 章策略建议

第 15 章关于我们公司/免责声明

Product Code: MX11076

Global postoperative pain market is projected to witness a CAGR of 5.25% during the forecast period 2024-2031, growing from USD 40.09 billion in 2023 to USD 60.36 billion in 2031. The market is anticipated to thrive under the influence of factors such as the increasing number of surgical procedures leading to high demands for efficient pain relief strategies and a rise in chronic conditions contributing to the necessity for effective post-surgical pain control. Additionally, concerns regarding opioid abuse have led to increased interest in exploring non-opioid alternatives for managing pain after surgery. Emphasis on improving patient compliance through eliminating post-operative pain is another major driving force for the market. Research and development initiatives driving innovation within the industry, providing novel approaches to reduce post-operative discomfort further expand the market. However, the major challenge for market expansion is the side effects associated with the use of opioid analgesic drugs and other complications with the use of pain management solutions. Drug abuse is another major concern related to pain management therapies as these methods involve the use of drug agents acting on the nervous system, leading to regulatory challenges.

For instance, in October 2023, Hyloris Pharma announced that it had received US FDA approval for the drug Maxigesic IV, which is meant to treat post-operative pain. Maxigesic IV contains a combination of paracetamol with ibuprofen solution for intravenous infusion, which helps in reducing postoperative pain and inflammation without the risk of opioid addiction. Hyloris Pharma is a Belgium-based company, and it developed the approved drug in collaboration with New Zealand-based drugmaker AFT Pharmaceuticals and Hikma Pharmaceuticals.

Increasing Number of Surgical Procedures

Most surgeries are necessary due to emergencies or other situations where only medication is not enough. The number of cancer cases requiring surgery, such as throat or mouth cancer, is rising globally. The demand for disposable surgical instruments is further propelled by chronic conditions like cardiovascular and gastrointestinal issues, and the surge in traffic accidents necessitating surgery. The market's significant expansion is aided by consumers' disposable income, which enables them to purchase these instruments. A high number of surgical procedures performed is directly linked with a high incidence of postoperative pain cases, and as the increase in both numbers is observed, the market expansion is promising. According to the World Health Organization (WHO), over 300 million surgical procedures are done globally annually. In October 2023, as per The Hindu, the rate of surgeries in India is between 166 and 3,646 surgeries per 100,000 individuals, depending on the setting, population, and other factors, while the population is about 1.4 billion. As per available data, more than 7 million surgical procedures were performed in the year 2022 within the United States.

Increasing Emphasis on Patient Compliance

Due to the rising emphasis on patient compliance, postoperative pain management has become a major concern. Many patients still experience moderate to severe pain after surgery, indicating inadequate postoperative pain management. The primary cause of this issue is insufficient analgesia prescription, not solely non-compliance. Patients' pain management can be neglected after discharge, so pain assessment, recording, and management are crucial aspects of care. Compliance with pain assessment in postoperative patients is vital, and the use of standard scales is recommended. Adequate analgesics and approved national pain guidelines are essential for effective pain management. Market players are constantly involved in product development and regulatory pathways to adequately cater to the market requirements.

In February 2024, Hikma Pharmaceuticals PLC announced the launch of COMBOGESIC IV injection in the United States market. COMBOGESIC IV is an opioid-free pain relief intravenous injection with a combination of 1000 mg acetaminophen and 300 mg ibuprofen. The combination drug was approved by the United States FDA in October 2023 for use in adults. Hikma Pharmaceuticals is a multinational pharmaceutical manufacturer working in a variety of indications and has a strong presence in the United States.

Dominance of Drug Segment and Fast Growth for Devices Segment

In the postoperative pain market, drugs are expected to dominate the product type category due to their extensive use in pain management compared to devices. Painkiller drugs, such as opioids, NSAIDs, and analgesics, are readily available and more cost-effective than pain management devices. The ease of administration without the need for medical assistance further contributes to the high usage of drugs. However, the adoption of pain management devices is increasing to avoid the side effects associated with drugs, leading to a higher growth rate in the pain management device segment. Despite the growing popularity of pain management devices, the drug segment is anticipated to dominate due to easy access, patient compliance, and cost-effectiveness.

In January 2024, Lupin launched a generic Bromfenac Ophthalmic Solution in the United States. This product is equivalent to Bausch & Lomb Inc.'s Prolensa ophthalmic solution, and it has received approval from the U.S. Food and Drug Administration. Lupin is the first company to file for this generic medication, granting it exclusive rights for 180 days. Bromfenac Ophthalmic Solution is intended to treat postoperative pain, and inflammation, along with alleviating eye discomfort in patients who have undergone cataract surgery.

Oral Route of Administration to be Leading Segment

In the management of postoperative pain, administering painkillers through the oral route is widely regarded as the most effective method, particularly if there are no contraindications. This approach excels in terms of simplicity, non-invasiveness, and patient acceptance compared to other routes such as injectables or inhalation. Oral opioids are effective in addressing acute pain, despite their slower action compared to injections. They are typically taken as pills that act rapidly or as sustained-release tablets. For better pain control, a combination of different types of pain relievers and non-drug therapies, known as multimodal analgesia, is commonly recommended over relying solely on opioids.

In February 2024, Cytogel Pharma's drug Cyt-1010 is undergoing clinical trials, specifically in Phase I for treating pain after surgery. Drugs in Phase I for this purpose typically have a high chance, around 87%, of moving forward to Phase II. Cyt-1010 is a distinct compound, like endomorphin 1, a natural pain regulator. It can be administered either orally or intravenously, interacting with Mu opioid receptors to manage pain.

North America to be the Dominating Region

North America is expected to dominate the market share throughout the assessment period owing to factors, including the high prevalence and severity of postoperative pain, the adoption of opioid management treatment to reduce the opioid epidemic, and the presence of a strong drug pipeline with effective drugs coming up for approvals by the US Food and Drug Administration. Additionally, the region has a high number of surgical procedures, increasing demand for pain management drugs, and rising awareness regarding post-surgery pain control. The presence of key market players like Novartis AG, Allergan plc., Teva Pharmaceutical Industries Ltd., Mylan N.V., and Pfizer Inc. in the region is another factor strengthening the lead of North America in the region. US FDA efforts to strengthen pain management methods also catalyze market growth.

In September 2023, the US FDA granted cooperative support to develop two clinical practice guidelines using evidence-based approaches. One guideline will focus on the treatment of recent-onset lower back pain, while the other will focus on the management of pain after laparoscopic abdominal surgery.

Future Market Scenario (2024 - 2031F)

In the future, postoperative pain management will most likely involve more acute pain services (APSs) and better communication among surgery, anesthesiology, and acute pain departments. The use of multimodal analgesics may enhance pain relief after surgery. The occurrence of chronic pain after surgery differs depending on the surgical complications but is very common. Innovative approaches, like transitional pain services, aim to improve the management of acute and chronic pain after surgery. Alongside, exploring new metabolic pathways and biological targets to provide pain relief without any drug abuse and product development seems like a promising concept for future growth of the market. For instance, in October 2023, South Rampart Pharma, a company focused on safer pain treatments, received Fast Track status for its promising drug, SRP-001, from the US FDA. SRP-001 stands out as a novel, non-addictive painkiller that operates differently from conventional opioids. The Fast Track designation is designed to accelerate the development and review process for promising therapies that address serious conditions. This pathway aims to ensure that patients have access to effective treatments quickly, thereby meeting pressing medical needs.

Key Players Landscape and Outlook

Novartis AG, Allergan plc, Teva Pharmaceutical Industries Ltd., Mylan N.V., Pfizer Inc., GlaxoSmithKline Plc., Johnson & Johnson Pte. Ltd., AstraZeneca PLC, Sanofi S.A., are some of the renowned players of the postoperative pain management market. These players actively invest time and money in innovative product developments and regulatory approvals. Market tactics like mergers and acquisitions and collaborations among market players are anticipated to further drive market expansion.

In November 2023, BehaVR and Fern Health joined forces to establish RealizedCare, a digital care management solution tailored for chronic pain. This collaboration aims to address the growing need for proven, scalable, and cost-effective interventions for mental and behavioral health issues, with an initial focus on chronic pain.

Table of Contents

1. Research Methodology

2. Project Scope & Definitions

3. Executive Summary

4. Global Postoperative Pain Market Outlook, 2017-2031F

  • 4.1. Market Size & Forecast
    • 4.1.1. By Value
    • 4.1.2. By Volume
  • 4.2. By Product
    • 4.2.1. Drugs
      • 4.2.1.1. Opioids
      • 4.2.1.2. Cyclooxygenase-2-Selective(COX-2) Inhibitors
      • 4.2.1.3. Non-steroidal Anti-inflammatory Drugs (NSAIDs)
      • 4.2.1.4. Anesthetics
      • 4.2.1.5. Anticonvulsants
      • 4.2.1.6. Anti-depressants
      • 4.2.1.7. Other Non-narcotic Analgesics
    • 4.2.2. Devices
      • 4.2.2.1. Neurostimulation Devices
      • 4.2.2.2. Brain and Spinal Cord Stimulation (SCS) Devices
      • 4.2.2.3. Analgesics Infusion Pumps
  • 4.3. By Route of Administration
    • 4.3.1. Injectable
    • 4.3.2. Oral
    • 4.3.3. Topical
    • 4.3.4. Transdermal
    • 4.3.5. Others
  • 4.4. By Distribution Channel
    • 4.4.1. Hospital Pharmacies
    • 4.4.2. Retail Pharmacies
    • 4.4.3. Online Pharmacies
  • 4.5. By Region
    • 4.5.1. North America
    • 4.5.2. Europe
    • 4.5.3. Asia-Pacific
    • 4.5.4. South America
    • 4.5.5. Middle East and Africa
  • 4.6. By Company Market Share (%), 2023

5. Global Postoperative Pain Market Outlook, By Region, 2017-2031F

  • 5.1. North America*
    • 5.1.1. Market Size & Forecast
      • 5.1.1.1. By Value
      • 5.1.1.2. By Volume
    • 5.1.2. By Product
      • 5.1.2.1. Drugs
      • 5.1.2.1.1. Opioids
      • 5.1.2.1.2. Cyclooxygenase-2-Selective(COX-2),Inhibitors
      • 5.1.2.1.3. Non-steroidal Anti-inflammatory Drugs (NSAIDs)
      • 5.1.2.1.4. Anesthetics
      • 5.1.2.1.5. Anticonvulsants
      • 5.1.2.1.6. Anti-depressants
      • 5.1.2.1.7. Other Non-narcotic Analgesics
      • 5.1.2.2. Devices
      • 5.1.2.2.1. Neurostimulation Devices
      • 5.1.2.2.2. Brain and Spinal Cord Stimulation (SCS) Devices
      • 5.1.2.2.3. Analgesics Infusion Pumps
    • 5.1.3. By Route of Administration
      • 5.1.3.1. Injectable
      • 5.1.3.2. Oral
      • 5.1.3.3. Topical
      • 5.1.3.4. Transdermal
      • 5.1.3.5. Others
    • 5.1.4. By Distribution Channel
      • 5.1.4.1. Hospital Pharmacies
      • 5.1.4.2. Retail Pharmacies
      • 5.1.4.3. Online Pharmacies
    • 5.1.5. United States*
      • 5.1.5.1. Market Size & Forecast
      • 5.1.5.1.1. By Value
      • 5.1.5.1.2. By Volume
      • 5.1.5.2. By Product
      • 5.1.5.2.1. Drugs
      • 5.1.5.2.1.1. Opioids
      • 5.1.5.2.1.2. Cyclooxygenase-2-Selective(COX-2),Inhibitors
      • 5.1.5.2.1.3. Non-steroidal Anti-inflammatory Drugs (NSAIDs)
      • 5.1.5.2.1.4. Anesthetics
      • 5.1.5.2.1.5. Anticonvulsants
      • 5.1.5.2.1.6. Anti-depressants
      • 5.1.5.2.1.7. Other Non-narcotic Analgesics
      • 5.1.5.2.2. Devices
      • 5.1.5.2.2.1. Neurostimulation Devices
      • 5.1.5.2.2.2. Brain and Spinal Cord Stimulation (SCS) Devices
      • 5.1.5.2.2.3. Analgesics Infusion Pumps
      • 5.1.5.3. By Route of Administration
      • 5.1.5.3.1. Injectable
      • 5.1.5.3.2. Oral
      • 5.1.5.3.3. Topical
      • 5.1.5.3.4. Transdermal
      • 5.1.5.3.5. Others
      • 5.1.5.4. By Distribution Channel
      • 5.1.5.4.1. Hospital Pharmacies
      • 5.1.5.4.2. Retail Pharmacies
      • 5.1.5.4.3. Online Pharmacies
    • 5.1.6. Canada
    • 5.1.7. Mexico

All segments will be provided for all regions and countries covered

  • 5.2. Europe
    • 5.2.1. Germany
    • 5.2.2. France
    • 5.2.3. Italy
    • 5.2.4. United Kingdom
    • 5.2.5. Russia
    • 5.2.6. Netherlands
    • 5.2.7. Spain
    • 5.2.8. Turkey
    • 5.2.9. Poland
  • 5.3. Asia-Pacific
    • 5.3.1. India
    • 5.3.2. China
    • 5.3.3. Japan
    • 5.3.4. Australia
    • 5.3.5. Vietnam
    • 5.3.6. South Korea
    • 5.3.7. Indonesia
    • 5.3.8. Philippines
  • 5.4. South America
    • 5.4.1. Brazil
    • 5.4.2. Argentina
  • 5.5. Middle East & Africa
    • 5.5.1. Saudi Arabia
    • 5.5.2. UAE
    • 5.5.3. South Africa

6. Market Mapping, 2023

  • 6.1. By Product
  • 6.2. By Route of Administration
  • 6.3. By Distribution Channel
  • 6.4. By Region

7. Macro Environment and Industry Structure

  • 7.1. Demand Supply Analysis
  • 7.2. Import Export Analysis
  • 7.3. Value Chain Analysis
  • 7.4. PESTEL Analysis
    • 7.4.1. Political Factors
    • 7.4.2. Economic System
    • 7.4.3. Social Implications
    • 7.4.4. Technological Advancements
    • 7.4.5. Environmental Impacts
    • 7.4.6. Legal Compliances and Regulatory Policies (Statutory Bodies Included)
  • 7.5. Porter's Five Forces Analysis
    • 7.5.1. Supplier Power
    • 7.5.2. Buyer Power
    • 7.5.3. Substitution Threat
    • 7.5.4. Threat from New Entrant
    • 7.5.5. Competitive Rivalry

8. Market Dynamics

  • 8.1. Growth Drivers
  • 8.2. Growth Inhibitors (Challenges and Restraints)

9. Regulatory Framework and Innovation

  • 9.1. Clinical Trials
  • 9.2. Patent Landscape
  • 9.3. Regulatory Approvals
  • 9.4. Innovations/Emerging Technologies

10. Key Players Landscape

  • 10.1. Competition Matrix of Top Five Market Leaders
  • 10.2. Market Revenue Analysis of Top Five Market Leaders (in %, 2023)
  • 10.3. Mergers and Acquisitions/Joint Ventures (If Applicable)
  • 10.4. SWOT Analysis (For Five Market Players)

11. Pricing Analysis

12. Case Studies

13. Key Players Outlook

  • 13.1. Novartis AG
    • 13.1.1. Company Details
    • 13.1.2. Key Management Personnel
    • 13.1.3. Products & Services
    • 13.1.4. Financials (As reported)
    • 13.1.5. Key Market Focus & Geographical Presence
    • 13.1.6. Recent Developments
  • 13.2. Allergan plc
  • 13.3. Teva Pharmaceutical Industries Ltd.
  • 13.4. Mylan N.V.
  • 13.5. Pfizer Inc.
  • 13.6. GlaxoSmithKline Plc.
  • 13.7. Johnson & Johnson Pte. Ltd.
  • 13.8. AstraZeneca PLC
  • 13.9. Sanofi S.A.
  • 13.10. Cipla Inc. (InvaGen Pharmaceuticals Inc.)

Companies mentioned above DO NOT hold any order as per market share and can be changed as per information available during research work.

14. Strategic Recommendations

15. About Us & Disclaimer

List of Tables

  • Table 1. Pricing Analysis of Products from Key Players
  • Table 2. Competition Matrix of Top 5 Market Leaders
  • Table 3. Mergers & Acquisitions/ Joint Ventures (If Applicable)
  • Table 4. About Us - Regions and Countries Where We Have Executed Client Projects

List of Figures

  • Figure 1. Global Postoperative Pain Market, By Value, in USD Billion, 2017-2031F
  • Figure 2. Global Postoperative Pain Market, By Volume, in Million Units, 2017-2031F
  • Figure 3. Global Postoperative Pain Market Share (%), By Product, 2017-2031F
  • Figure 4. Global Postoperative Pain Market Share (%), By Route of Administration, 2017-2031F
  • Figure 5. Global Postoperative Pain Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 6. Global Postoperative Pain Market Share (%), By Region, 2017-2031F
  • Figure 7. North America Postoperative Pain Market, By Value, in USD Billion, 2017-2031F
  • Figure 8. North America Postoperative Pain Market, By Volume, in Million Units, 2017-2031F
  • Figure 9. North America Postoperative Pain Market Share (%), By Product, 2017-2031F
  • Figure 10. North America Postoperative Pain Market Share (%), By Route of Administration, 2017-2031F
  • Figure 11. North America Postoperative Pain Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 12. North America Postoperative Pain Market Share (%), By Country, 2017-2031F
  • Figure 13. United States Postoperative Pain Market, By Value, in USD Billion, 2017-2031F
  • Figure 14. United States Postoperative Pain Market, By Volume, in Million Units, 2017-2031F
  • Figure 15. United States Postoperative Pain Market Share (%), By Product, 2017-2031F
  • Figure 16. United States Postoperative Pain Market Share (%), By Route of Administration, 2017-2031F
  • Figure 17. United States Postoperative Pain Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 18. Canada Postoperative Pain Market, By Value, in USD Billion, 2017-2031F
  • Figure 19. Canada Postoperative Pain Market, By Volume, in Million Units, 2017-2031F
  • Figure 20. Canada Postoperative Pain Market Share (%), By Product, 2017-2031F
  • Figure 21. Canada Postoperative Pain Market Share (%), By Route of Administration, 2017-2031F
  • Figure 22. Canada Postoperative Pain Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 23. Mexico Postoperative Pain Market, By Value, in USD Billion, 2017-2031F
  • Figure 24. Mexico Postoperative Pain Market, By Volume, in Million Units, 2017-2031F
  • Figure 25. Mexico Postoperative Pain Market Share (%), By Product, 2017-2031F
  • Figure 26. Mexico Postoperative Pain Market Share (%), By Route of Administration, 2017-2031F
  • Figure 27. Mexico Postoperative Pain Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 28. Europe Postoperative Pain Market, By Value, in USD Billion, 2017-2031F
  • Figure 29. Europe Postoperative Pain Market, By Volume, in Million Units, 2017-2031F
  • Figure 30. Europe Postoperative Pain Market Share (%), By Product, 2017-2031F
  • Figure 31. Europe Postoperative Pain Market Share (%), By Route of Administration, 2017-2031F
  • Figure 32. Europe Postoperative Pain Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 33. Europe Postoperative Pain Market Share (%), By Country, 2017-2031F
  • Figure 34. Germany Postoperative Pain Market, By Value, in USD Billion, 2017-2031F
  • Figure 35. Germany Postoperative Pain Market, By Volume, in Million Units, 2017-2031F
  • Figure 36. Germany Postoperative Pain Market Share (%), By Product, 2017-2031F
  • Figure 37. Germany Postoperative Pain Market Share (%), By Route of Administration, 2017-2031F
  • Figure 38. Germany Postoperative Pain Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 39. France Postoperative Pain Market, By Value, in USD Billion, 2017-2031F
  • Figure 40. France Postoperative Pain Market, By Volume, in Million Units, 2017-2031F
  • Figure 41. France Postoperative Pain Market Share (%), By Product, 2017-2031F
  • Figure 42. France Postoperative Pain Market Share (%), By Route of Administration, 2017-2031F
  • Figure 43. France Postoperative Pain Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 44. Italy Postoperative Pain Market, By Value, in USD Billion, 2017-2031F
  • Figure 45. Italy Postoperative Pain Market, By Volume, in Million Units, 2017-2031F
  • Figure 46. Italy Postoperative Pain Market Share (%), By Product, 2017-2031F
  • Figure 47. Italy Postoperative Pain Market Share (%), By Route of Administration, 2017-2031F
  • Figure 48. Italy Postoperative Pain Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 49. United Kingdom Postoperative Pain Market, By Value, in USD Billion, 2017-2031F
  • Figure 50. United Kingdom Postoperative Pain Market, By Volume, in Million Units, 2017-2031F
  • Figure 51. United Kingdom Postoperative Pain Market Share (%), By Product, 2017-2031F
  • Figure 52. United Kingdom Postoperative Pain Market Share (%), By Route of Administration, 2017-2031F
  • Figure 53. United Kingdom Postoperative Pain Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 54. Russia Postoperative Pain Market, By Value, in USD Billion, 2017-2031F
  • Figure 55. Russia Postoperative Pain Market, By Volume, in Million Units, 2017-2031F
  • Figure 56. Russia Postoperative Pain Market Share (%), By Product, 2017-2031F
  • Figure 57. Russia Postoperative Pain Market Share (%), By Route of Administration, 2017-2031F
  • Figure 58. Russia Postoperative Pain Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 59. Netherlands Postoperative Pain Market, By Value, in USD Billion, 2017-2031F
  • Figure 60. Netherlands Postoperative Pain Market, By Volume, in Million Units, 2017-2031F
  • Figure 61. Netherlands Postoperative Pain Market Share (%), By Product, 2017-2031F
  • Figure 62. Netherlands Postoperative Pain Market Share (%), By Route of Administration, 2017-2031F
  • Figure 63. Netherlands Postoperative Pain Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 64. Spain Postoperative Pain Market, By Value, in USD Billion, 2017-2031F
  • Figure 65. Spain Postoperative Pain Market, By Volume, in Million Units, 2017-2031F
  • Figure 66. Spain Postoperative Pain Market Share (%), By Product, 2017-2031F
  • Figure 67. Spain Postoperative Pain Market Share (%), By Route of Administration, 2017-2031F
  • Figure 68. Spain Postoperative Pain Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 69. Turkey Postoperative Pain Market, By Value, in USD Billion, 2017-2031F
  • Figure 70. Turkey Postoperative Pain Market, By Volume, in Million Units, 2017-2031F
  • Figure 71. Turkey Postoperative Pain Market Share (%), By Product, 2017-2031F
  • Figure 72. Turkey Postoperative Pain Market Share (%), By Route of Administration, 2017-2031F
  • Figure 73. Turkey Postoperative Pain Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 74. Poland Postoperative Pain Market, By Value, in USD Billion, 2017-2031F
  • Figure 75. Poland Postoperative Pain Market, By Volume, in Million Units, 2017-2031F
  • Figure 76. Poland Postoperative Pain Market Share (%), By Product, 2017-2031F
  • Figure 77. Poland Postoperative Pain Market Share (%), By Route of Administration, 2017-2031F
  • Figure 78. Poland Postoperative Pain Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 79. South America Postoperative Pain Market, By Value, in USD Billion, 2017-2031F
  • Figure 80. South America Postoperative Pain Market, By Volume, in Million Units, 2017-2031F
  • Figure 81. South America Postoperative Pain Market Share (%), By Product, 2017-2031F
  • Figure 82. South America Postoperative Pain Market Share (%), By Route of Administration, 2017-2031F
  • Figure 83. South America Postoperative Pain Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 84. South America Postoperative Pain Market Share (%), By Country, 2017-2031F
  • Figure 85. Brazil Postoperative Pain Market, By Value, in USD Billion, 2017-2031F
  • Figure 86. Brazil Postoperative Pain Market, By Volume, in Million Units, 2017-2031F
  • Figure 87. Brazil Postoperative Pain Market Share (%), By Product, 2017-2031F
  • Figure 88. Brazil Postoperative Pain Market Share (%), By Route of Administration, 2017-2031F
  • Figure 89. Brazil Postoperative Pain Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 90. Argentina Postoperative Pain Market, By Value, in USD Billion, 2017-2031F
  • Figure 91. Argentina Postoperative Pain Market, By Volume, in Million Units, 2017-2031F
  • Figure 92. Argentina Postoperative Pain Market Share (%), By Product, 2017-2031F
  • Figure 93. Argentina Postoperative Pain Market Share (%), By Route of Administration, 2017-2031F
  • Figure 94. Argentina Postoperative Pain Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 95. Asia-Pacific Postoperative Pain Market, By Value, in USD Billion, 2017-2031F
  • Figure 96. Asia-Pacific Postoperative Pain Market, By Volume, in Million Units, 2017-2031F
  • Figure 97. Asia-Pacific Postoperative Pain Market Share (%), By Product, 2017-2031F
  • Figure 98. Asia-Pacific Postoperative Pain Market Share (%), By Route of Administration, 2017-2031F
  • Figure 99. Asia-Pacific Postoperative Pain Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 100. Asia-Pacific Postoperative Pain Market Share (%), By Country, 2017-2031F
  • Figure 101. India Postoperative Pain Market, By Value, in USD Billion, 2017-2031F
  • Figure 102. India Postoperative Pain Market, By Volume, in Million Units, 2017-2031F
  • Figure 103. India Postoperative Pain Market Share (%), By Product, 2017-2031F
  • Figure 104. India Postoperative Pain Market Share (%), By Route of Administration, 2017-2031F
  • Figure 105. India Postoperative Pain Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 106. China Postoperative Pain Market, By Value, in USD Billion, 2017-2031F
  • Figure 107. China Postoperative Pain Market, By Volume, in Million Units, 2017-2031F
  • Figure 108. China Postoperative Pain Market Share (%), By Product, 2017-2031F
  • Figure 109. China Postoperative Pain Market Share (%), By Route of Administration, 2017-2031F
  • Figure 110. China Postoperative Pain Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 111. Japan Postoperative Pain Market, By Value, in USD Billion, 2017-2031F
  • Figure 112. Japan Postoperative Pain Market, By Volume, in Million Units, 2017-2031F
  • Figure 113. Japan Postoperative Pain Market Share (%), By Product, 2017-2031F
  • Figure 114. Japan Postoperative Pain Market Share (%), By Route of Administration, 2017-2031F
  • Figure 115. Japan Postoperative Pain Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 116. Australia Postoperative Pain Market, By Value, in USD Billion, 2017-2031F
  • Figure 117. Australia Postoperative Pain Market, By Volume, in Million Units, 2017-2031F
  • Figure 118. Australia Postoperative Pain Market Share (%), By Product, 2017-2031F
  • Figure 119. Australia Postoperative Pain Market Share (%), By Route of Administration, 2017-2031F
  • Figure 120. Australia Postoperative Pain Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 121. Vietnam Postoperative Pain Market, By Value, in USD Billion, 2017-2031F
  • Figure 122. Vietnam Postoperative Pain Market, By Volume, in Million Units, 2017-2031F
  • Figure 123. Vietnam Postoperative Pain Market Share (%), By Product, 2017-2031F
  • Figure 124. Vietnam Postoperative Pain Market Share (%), By Route of Administration, 2017-2031F
  • Figure 125. Vietnam Postoperative Pain Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 126. South Korea Postoperative Pain Market, By Value, in USD Billion, 2017-2031F
  • Figure 127. South Korea Postoperative Pain Market, By Volume, in Million Units, 2017-2031F
  • Figure 128. South Korea Postoperative Pain Market Share (%), By Product, 2017-2031F
  • Figure 129. South Korea Postoperative Pain Market Share (%), By Route of Administration, 2017-2031F
  • Figure 130. South Korea Postoperative Pain Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 131. Indonesia Postoperative Pain Market, By Value, in USD Billion, 2017-2031F
  • Figure 132. Indonesia Postoperative Pain Market, By Volume, in Million Units, 2017-2031F
  • Figure 133. Indonesia Postoperative Pain Market Share (%), By Product, 2017-2031F
  • Figure 134. Indonesia Postoperative Pain Market Share (%), By Route of Administration, 2017-2031F
  • Figure 135. Indonesia Postoperative Pain Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 136. Philippines Postoperative Pain Market, By Value, in USD Billion, 2017-2031F
  • Figure 137. Philippines Postoperative Pain Market, By Volume, in Million Units, 2017-2031F
  • Figure 138. Philippines Postoperative Pain Market Share (%), By Product, 2017-2031F
  • Figure 139. Philippines Postoperative Pain Market Share (%), By Route of Administration, 2017-2031F
  • Figure 140. Philippines Postoperative Pain Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 141. Middle East & Africa Postoperative Pain Market, By Value, in USD Billion, 2017-2031F
  • Figure 142. Middle East & Africa Postoperative Pain Market, By Volume, in Million Units, 2017-2031F
  • Figure 143. Middle East & Africa Postoperative Pain Market Share (%), By Product, 2017-2031F
  • Figure 144. Middle East & Africa Postoperative Pain Market Share (%), By Route of Administration, 2017-2031F
  • Figure 145. Middle East & Africa Postoperative Pain Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 146. Middle East & Africa Postoperative Pain Market Share (%), By Country, 2017-2031F
  • Figure 147. Saudi Arabia Postoperative Pain Market, By Value, in USD Billion, 2017-2031F
  • Figure 148. Saudi Arabia Postoperative Pain Market, By Volume, in Million Units, 2017-2031F
  • Figure 149. Saudi Arabia Postoperative Pain Market Share (%), By Product, 2017-2031F
  • Figure 150. Saudi Arabia Postoperative Pain Market Share (%), By Route of Administration, 2017-2031F
  • Figure 151. Saudi Arabia Postoperative Pain Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 152. UAE Postoperative Pain Market, By Value, in USD Billion, 2017-2031F
  • Figure 153. UAE Postoperative Pain Market, By Volume, in Million Units, 2017-2031F
  • Figure 154. UAE Postoperative Pain Market Share (%), By Product, 2017-2031F
  • Figure 155. UAE Postoperative Pain Market Share (%), By Route of Administration, 2017-2031F
  • Figure 156. UAE Postoperative Pain Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 157. South Africa Postoperative Pain Market, By Value, in USD Billion, 2017-2031F
  • Figure 158. South Africa Postoperative Pain Market, By Volume, in Million Units, 2017-2031F
  • Figure 159. South Africa Postoperative Pain Market Share (%), By Product, 2017-2031F
  • Figure 160. South Africa Postoperative Pain Market Share (%), By Route of Administration, 2017-2031F
  • Figure 161. South Africa Postoperative Pain Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 162. By Product Map-Market Size (USD Billion) & Growth Rate (%), 2023
  • Figure 163. By Route of Administration Map-Market Size (USD Billion) & Growth Rate (%), 2023
  • Figure 164. By Distribution Channel Map-Market Size (USD Billion) & Growth Rate (%), 2023
  • Figure 165. By Region Map-Market Size (USD Billion) & Growth Rate (%), 2023